Cgm Dexcom denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for cgm dexcom are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Your Dexcom CGM as Experimental

An "experimental or investigational" denial from Aetna means the plan has concluded that the Dexcom continuous glucose monitor lacks sufficient evidence of clinical effectiveness for your specific indication or patient population. This denial language is sometimes applied when a CGM is prescribed for a diabetes type or treatment regimen that Aetna's current medical policy does not yet list as a covered indication, even if the device itself has broad FDA clearance.

This denial is highly appealable. Dexcom CGM systems carry FDA clearance for diabetes management, and the body of peer-reviewed evidence supporting CGM use across multiple diabetes populations is extensive. The key is to show that your specific clinical situation falls squarely within an evidence-supported, guideline-endorsed use case.

## Your Federal Appeal Rights

• Internal appeal: File within the deadline on your denial notice. Aetna must respond within 30 days (non-urgent) or 72 hours (expedited).
• External review (ACA §2719 / ERISA §503): After a final internal denial, you may request independent external review — typically within approximately four months. An IRO applies objective clinical standards, not Aetna's internal policy, and its decision is binding.
• Expedited option: If delay would seriously jeopardize your health, request expedited internal and external review simultaneously.

## Documentation to Gather

1. FDA clearance confirmation: Note the device's FDA-cleared indication as stated in the product labeling — this directly rebuts an "unapproved" or "investigational" framing. 2. Prescriber medical-necessity letter: Your physician should explain how your case fits an evidence-supported indication and reference the relevant guideline organization (e.g., American Diabetes Association, American Association of Clinical Endocrinology) without inventing statistics. 3. Clinical chart notes: Documentation of your diagnosis, treatment regimen, and any prior glucose monitoring history showing why CGM is clinically appropriate. 4. Published guideline references: Copies of or citations to current professional society guidance endorsing CGM for patients with your profile — the organization name and publication year are sufficient; your prescriber need not quote specific numbers. 5. Relevant peer-reviewed literature: Your prescriber or an appeals specialist can attach published reviews supporting CGM effectiveness in your indication.

## Criteria-Mapping Structure

Obtain Aetna's CGM medical policy document. For each criterion the policy uses to define "proven" versus "experimental," document the specific chart evidence that places your case in the proven category. If Aetna's policy restricts coverage to certain insulin regimens or clinical presentations, map your chart notes directly to those requirements line by line.

Experimental denials for FDA-cleared devices with strong guideline support are among the most commonly reversed on external review. A precise, evidence-grounded appeal letter makes a significant difference.